生物公司将从TJ Biopharma获得费尔扎塔马布的权利, Biogen to acquire felzartamab rights from TJ Biopharma for up to $850M.

生物公司已同意从TJ Biopharma获得在中国开发和销售felzartamab的独家权利,价格高达8.5亿美元. Biogen has agreed to acquire exclusive rights to develop and sell felzartamab in China from TJ Biopharma for up to $850 million. 协议包括1亿美元的预付款和潜在的里程碑, The agreement includes a $100 million upfront payment and potential milestones based on development and sales. 目前该药物正在免疫疾病的第三阶段临床试验中. The drug is currently in Phase 3 clinical trials for immune diseases.